Skip to content
The Weight Clinic
← Blog Compare treatments

Mounjaro vs Wegovy: are the side effects different?

Two weight-loss injection pens side by side representing Mounjaro and Wegovy
Medically reviewed by Ali Al Sibahi, Pharmacist Independent Prescriber (GPhC 2225108) · 22 November 2026

Mounjaro (tirzepatide) and Wegovy (semaglutide) share almost the same side-effect profile, because both work on the gut-hormone GLP-1 pathway. The most common effects for both are nausea, diarrhoea, constipation, vomiting, reduced appetite and fatigue, and both carry the same rare but serious risks, including acute pancreatitis and severe allergic reaction.

The main difference is mechanism, not a fundamentally different list of side effects. Mounjaro activates two receptors (GLP-1 and GIP), while Wegovy activates one (GLP-1). Below is a practical, UK-focused comparison of what to expect, why these effects happen, and when to seek help.

What side effects do Mounjaro and Wegovy have in common?

Mounjaro and Wegovy share the same core side-effect profile because both act on the GLP-1 system, which slows stomach emptying and reduces appetite. The common effects (affecting more than 1 in 10 people) for both medicines are nausea, diarrhoea, constipation, vomiting, decreased appetite and fatigue.

These gastrointestinal effects happen because the medicine slows how quickly your stomach empties and changes appetite signalling. They are usually mild to moderate, tend to be strongest just after a dose increase, and often settle as your body adjusts over a few weeks.

How do the serious but rare risks compare?

The serious but rare risks are essentially the same for both Mounjaro and Wegovy, because they belong to the same medicine class. Both list severe allergic reaction, acute pancreatitis, severe hypoglycaemia (low blood sugar, more likely if combined with certain diabetes medicines), severe gastrointestinal disease, and worsening diabetic retinopathy in people with diabetes.

These events are uncommon, but they matter. Stop the medicine and seek urgent medical advice if you develop severe, persistent abdominal pain (a possible sign of pancreatitis), signs of a serious allergic reaction, or symptoms of severe dehydration from prolonged vomiting or diarrhoea.

Does Mounjaro cause more side effects than Wegovy because it hits two receptors?

Activating two receptors does not automatically mean more or worse side effects. Mounjaro acts on both GLP-1 and GIP receptors, while Wegovy acts on GLP-1 alone, but both share the same documented common side effects and the same serious rare risks.

Side-effect intensity depends far more on the individual, the dose, and how quickly the dose is increased than on which of the two medicines you take. There is no reliable way to predict in advance who will tolerate one better than the other, which is why both are introduced at a low starter dose and increased gradually.

Why does gradual dose titration reduce side effects?

Both medicines are titrated slowly to give your digestive system time to adapt, which reduces the intensity of nausea and other gut symptoms. Starting high would make side effects far more likely and more severe.

Mounjaro starts at 2.5mg weekly and steps up through 5, 7.5, 10 and 12.5mg to a maximum licensed 15mg. The Wegovy injection starts at 0.25mg weekly and steps up through 0.5, 1, 1.7 and 2.4mg to a maximum licensed 7.2mg. Each increase is reviewed by a prescriber, and you only move up when you are tolerating the current dose.

How can you reduce side effects from either injection?

Most people manage the common gut side effects of both Mounjaro and Wegovy with simple practical steps, especially in the first few weeks and after each dose increase.

  • Eat smaller portions and stop when you feel full, since both medicines make you feel full sooner.
  • Favour bland, lower-fat foods when nausea is at its worst, and eat slowly.
  • Stay well hydrated, particularly if you have diarrhoea or vomiting, to avoid dehydration.
  • For constipation, increase fibre and fluids and keep moving.
  • Tell your prescriber if side effects are severe or not settling — slowing the titration can help.

Mounjaro vs Wegovy side effects at a glance

Side-effect comparison of Mounjaro (tirzepatide) and Wegovy injection (semaglutide)
FeatureMounjaro (tirzepatide)Wegovy injection (semaglutide)
Receptors targetedGLP-1 and GIP (dual)GLP-1 (single)
Common side effects (>1 in 10)Nausea, diarrhoea, constipation, vomiting, decreased appetite, fatigueSame GLP-1 class profile: nausea, diarrhoea, constipation, vomiting, decreased appetite, fatigue
Serious but rare risksSevere allergic reaction, acute pancreatitis, severe hypoglycaemia, severe GI disease, worsening diabetic retinopathySame GLP-1 class risks as Mounjaro
DosingWeekly self-injection, 2.5mg up to 15mg maxWeekly self-injection, 0.25mg up to 7.2mg max
Trial weight-loss figure22.5% at 15mg over 72 weeks (SURMOUNT-1)*20.7% at 7.2mg over 72 weeks (STEP UP)*

*In the SURMOUNT-1 trial, participants on the Mounjaro 15mg dose lost on average 22.5% of body weight over 72 weeks, alongside lifestyle support. In the STEP UP trial, adults on the Wegovy 7.2mg dose lost on average 20.7% of their body weight over 72 weeks, alongside lifestyle support. These are separate trials, not a head-to-head comparison. Individual results vary; not everyone reaches this.

What about the tablet options?

If you would rather not inject, there are oral GLP-1 options with the same class side-effect profile. The Wegovy Tablet is the same active medicine as the Wegovy injection, taken as a once-daily tablet first thing on an empty stomach with a small sip of plain water, then waiting at least 30 minutes before eating or drinking anything else. Foundayo (orforglipron) is a small-molecule GLP-1 tablet taken once daily at any time of day, with or without food or water.

Both tablets share the common GLP-1 side effects — nausea, diarrhoea, constipation, vomiting, reduced appetite and fatigue — and the same serious but rare risks as the injections. You can see all the treatment options together to compare.

Who is not suitable for either medicine?

Both Mounjaro and Wegovy are prescription-only and are not suitable for everyone, regardless of side-effect tolerance. You should not use either if you are pregnant, planning pregnancy or breastfeeding; have type 1 diabetes; have a personal or family history of medullary thyroid carcinoma or MEN2; have a history of pancreatitis; have severe gastrointestinal disease; have an active eating disorder; have severe liver or kidney impairment; or are allergic to the active ingredient.

Eligibility generally requires being aged 18 or over with a BMI of 30 or more, or a BMI of 27 to 30 with a weight-related condition such as type 2 diabetes, high blood pressure or sleep apnoea. A GPhC-registered prescriber decides whether treatment is clinically appropriate for you.

How do you report a side effect in the UK?

You can report any suspected side effect from Mounjaro, Wegovy or any medicine through the MHRA Yellow Card scheme at https://yellowcard.mhra.gov.uk/. Reporting helps the MHRA monitor the safety of medicines in real-world use.

If you are deciding between these treatments, the safest first step is a clinical review of your health and history. You can begin a free online consultation, after which a registered prescriber will advise whether a treatment is appropriate for you.

This article is for information only and is not a substitute for personalised medical advice. Weight-loss medicines are prescription-only, are not suitable for everyone, and are prescribed only after a clinical consultation with a GPhC-registered prescriber. Individual results vary. Always speak to a UK-registered pharmacist or doctor before starting or changing any prescription medication.

Related reading

Check eligibility →